Dalbavancin (Dalbavancin)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antibiotics

Included in the formulation
  • Ksidalba TM
    lyophilizate d / infusion 
    Aziande Kimike Riounite Angelini Francesco AKR.A.A. SpA     Italy
    • АТХ:

    J.01.X.A.04   Dalbavancin

    Pharmacodynamics:

    The glycopeptide antibiotic binds the acyl-D-alanyl-D-alanine mucopeptide and breaks the synthesis of the cell wall, blocking the formation of the bacterial membrane, as a result of which the formation of spheroplasts ceases.

    It is active against gram-positive microflora: staphylococci, streptococci, micrococci, enterococci, corynebacteria, as well as peptococci and gram-positive anaerobes.

    Pharmacokinetics:

    After intravenous administration, the bioavailability is 96%. The connection with plasma proteins is 93%.

    Metabolism in the liver.

    The elimination half-life is 8.5 days. Elimination by the kidneys.

    Indications:

    It is used to treat infectious lesions of the skin and soft tissues.

    ICD-10

    XII.L00-L08.L08.9   Local infection of skin and subcutaneous tissue, unspecified

    XIII.M70-M79.M79.9   Soft tissue disorder, unspecified

    Contraindications:

    Acute renal failure, age 18 years, pregnancy and lactation, individual intolerance to glycopeptides.

    Carefully:

    Hepatic insufficiency, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Intravenously drip, for 30 minutes, 1.5 g once a week.

    The highest daily dose: 1.5 g.

    The highest single dose: 1.5 g.

    Side effects:

    Central and peripheral nervous system: headache, insomnia, depression, confused consciousness, dizziness, unsteadiness of gait, rarely - depression.

    Respiratory system: nasal congestion, bronchospasm, dyspnea.

    Hemopoietic system: leukopenia, neutropenia, agranulocytosis, thrombocytopenia, eosinophilia.

    The cardiovascular system: hyperemia of the face, sensation of hot flashes, thrombophlebitis with intravenous injection.

    Digestive system: decreased appetite, nausea, vomiting, diarrhea, increased levels of alkaline phosphatase and liver transaminases.

    Dermatological reactions: exfoliative dermatitis, toxic skin necrosis, Stevens-Johnson syndrome, abscess at the injection site.

    Sense organs: tinnitus, hearing loss, blurred vision.

    Urinary system: renal failure, urinary tract infections.

    Reproductive system: Candida colpitis.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Pharmacologically incompatible with saline solutions - precipitates.

    With simultaneous use with amphotericin B, aminoglycosides, furosemide and cyclosporine increases the risk of oto- and nephrotoxic effects.

    Special instructions:

    For intravenous infusion, a 5% dextrose solution is used.

    When taking the drug is not recommended driving and working with moving machinery.

    Instructions
    Up